Nanexa AB - Home

Where Nanoengineering
Meets Drug Delivery

Nanexa’s PharmaShell® technology is transforming the face of long-acting ’super generic’ drugs with its proprietary suite of Atomic Layer Deposition (ALD) technologies.
PharmaShell formulations will allow indications including type 2 diabetes/obesity, cancers, cardiovascular and psychiatric disorders to be treated with monthly injections.

PRESSRELEASES

27 January, 2026

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.
Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.

10 December, 2025

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.